Agios Pharmaceuticals (LSE:0HB0) - Stock Price, News & Analysis

0HB0 Stock Overview

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More details

0HB0 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 78.6% below our estimate of its fair value

Revenue is forecast to grow 55.42% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Earnings are forecast to decline by an average of 56.7% per year for the next 3 years

Volatile share price over the past 3 months compared to the UK market

Shareholders have been diluted in the past year

Agios Pharmaceuticals, Inc. Competitors

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£193.6m

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

PharmaEssentia

TWSE:6446

NT$189.7b

Price History & Performance

Summary of all time highs, changes and price drops for Agios Pharmaceuticals
Historical stock prices
Current Share Price	US$55.24
52 Week High	US$62.60
52 Week Low	US$21.03
Beta	0.75
11 Month Change	23.03%
3 Month Change	20.03%
1 Year Change	151.06%
33 Year Change	45.30%
5 Year Change	66.19%
Change since IPO	-31.57%

Recent updates

Shareholder Returns

	0HB0	GB Biotechs	GB Market
7D	-1.7%	-5.2%	0.8%
1Y	151.1%	-20.1%	6.6%

Return vs Industry: 0HB0 exceeded the UK Biotechs industry which returned -18.9% over the past year.

Return vs Market: 0HB0 exceeded the UK Market which returned 6.1% over the past year.

Price Volatility

Is 0HB0's price volatile compared to industry and market?
0HB0 volatility
0HB0 Average Weekly Movement	7.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0HB0's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HB0's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2007	385	Brian Goff	www.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Agios Pharmaceuticals, Inc. Fundamentals Summary

How do Agios Pharmaceuticals's earnings and revenue compare to its market cap?
0HB0 fundamental statistics
Market cap	US$3.11b
Earnings (TTM)	US$674.31m
Revenue (TTM)	US$32.87m

4.7x

P/E Ratio

96.4x

P/S Ratio

Is 0HB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HB0 income statement (TTM)
Revenue	US$32.87m
Cost of Revenue	US$299.46m
Gross Profit	-US$266.58m
Other Expenses	-US$940.89m
Earnings	US$674.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	11.82
Gross Margin	-811.00%
Net Profit Margin	2,051.38%
Debt/Equity Ratio	0%

How did 0HB0 perform over the long term?

See historical performance and comparison

0HB0 Stock Overview

Rewards

Risk Analysis

Agios Pharmaceuticals, Inc. Competitors

LSE:GNS

UK£1.1b

AIM:BVXP

UK£193.6m

LSE:HIK

UK£4.2b

TWSE:6446

NT$189.7b

Price History & Performance

Recent News & Updates

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

New major risk - Revenue and earnings growth

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Recent updates

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

New major risk - Revenue and earnings growth

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Forecast to breakeven in 2024

Second quarter 2024 earnings released: US$1.69 loss per share (vs US$1.51 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023)

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022)

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022)

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022)

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index